InvivydIVVD -3.16%27 Receivables Turnover is 1.08 as of Mar. 2026. GuruFocus rates IVVD with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 840 Biotechnology companies, Invivyd ranks better than 50% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Invivyd's Revenue for the
three
months ended in Mar. 2026 was $13.74 Mil. Invivyd's average Accounts Receivable for the
three
months ended in Mar. 2026 was $12.78 Mil.
Hence, Invivyd's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.08.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Invivyd Receivables Turnover Related Terms
Invivyd Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Invivyd's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVVD vs NAUT, ACIU, OTLK: Receivables Turnover Comparison
For the Biotechnology subindustry, Invivyd's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invivyd Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invivyd's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Invivyd's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invivyd (IVVD) has a Receivables Turnover of 1.08 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Invivyd and its competitors. According to the industry distribution chart, Invivyd ranks #420 out of 840 companies in the Biotechnology industry, placing it in the top 50%.
Is Invivyd's Receivables Turnover too high?
Invivyd's current Receivables Turnover is 1.08. The Biotechnology industry median Receivables Turnover is 5.30. Invivyd's value of 1.08 is 79.6% below this industry median. Based on the distribution chart, Invivyd ranks #420 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Invivyd has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Invivyd's Receivables Turnover compare to NAUT and ACIU?
According to the Biotechnology industry distribution chart, Invivyd ranks #420 out of 840 companies for Receivables Turnover. This puts Invivyd in the upper half of its industry. The industry median Receivables Turnover is 5.30. Invivyd's value of 1.08 is 79.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invivyd's current Receivables Turnover of 1.08 is 79.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Invivyd and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invivyd's current Receivables Turnover is 1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invivyd stock overvalued right now?
Invivyd (IVVD) has a current Receivables Turnover of 1.08. The current Receivables Turnover is 1.08 and 79.6% below the Biotechnology industry median of 5.30. Invivyd's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Invivyd (IVVD), the current Receivables Turnover is 1.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
27GF Score
Get the complete analysis for IVVD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVVD has been successfully added to your 
